


CDC SCOTS GP LIMITED

SC 379812

FINANCIAL STATEMENTS

7 JUNE 2010 - 31 DECEMBER 2010

WEDNESDAY



SQW96YB2

SCT

12/10/2011

55

COMPANIES HOUSE

CDC SCOTS GP LIMITED

Index to the financial statements
For the period 7 June 2010 to 31 December 2010

	Page
Directors' report	1
Statement of comprehensive income	2
Statement of financial position	3
Statement of changes in deficit	4
Statement of cash flows	5
Notes to the financial statements	6 - 8
Appendix –CDC Scots LP financial statements	9 -17

CDC SCOTS GP LIMITED

Directors' report

For the period 7 June 2010 to 31 December 2010

The directors are pleased to present their report together with the financial statements of the Company for the period ended 31 December 2010.

Directors

Godfrey Davies
Richard Laing

Appointed 7 June 2010

Appointed 7 June 2010

Principal activity

The principal activity of the Company is that of acting as a general partner to partnerships whose main activity is that of investment holding.

Business and performance review

The Company recorded a net profit of \$237 for the period from incorporation (7 June 2010) to the period end date of 31 December 2010. The net asset value of the Company was \$240 at 31 December 2010.

The directors do not recommend the payment of a dividend for the period.

Principal risks

The Company acts as a general partner to partnerships investing in private equity funds in developing countries. The Company values its portfolio according to CDC Group plc's (CDC) valuation methodology. CDC valuation guidelines have been developed in accordance with the International Private Equity and Venture Capital Valuation Guidelines. Investments are valued at fair value, which is the value at which an orderly transaction would take place between market participants at the reporting date.

The detailed valuation methodology sets out best practice with respect to valuing investments.

Valuation risks are mitigated by comprehensive reviews of underlying investments in the private equity funds carried out by the managers of the private equity funds at least twice each year.

On behalf of the board



Godfrey Davies
Director

CDC SCOTS GP LIMITED

Statement of comprehensive income
For the period 7 June 2010 to 31 December 2010

	US\$
Revenues	
Half of annual priority share	500
	500
Expenses	
General and administrative expenses	(170)
	(170)
Operating profit	330
Taxation	(93)
Net profit and comprehensive profit for the period	237

The accompanying notes on pages 6 to 8 form an integral part of these non-consolidated financial statements.

CDC SCOTS GP LIMITED

Statement of financial position
At 31 December 2010

	US\$
ASSETS	
Non-current assets	
Equity investments	1
Total non current assets	1
Current assets	
Cash and cash equivalents	501
Total current assets	501
Total assets	502
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current liabilities	
Accounts payable and accrued liabilities	93
Amounts due to parent company	170
Total current liabilities	263
Shareholders' equity	
Issued capital	2
Accumulated reserves	237
Total shareholders' equity	239
Total shareholders' equity and liabilities	502

The accompanying notes on pages 6 to 8 form an integral part of these non-consolidated financial statements.


For the year ending 31st December 2010 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved on behalf of the board on 10th October 2011



Godfrey Davies, Director of CDC Scots GP Limited (Company number 379812)

CDC SCOTS GP LIMITED

Statement of changes in equity
For the period 7 June 2010 to 31 December 2010

	Share capital US\$	Accumulated reserve US\$	Total US\$
At June 7, 2010	-	-	-
Issue of share capital	2	-	2
Net profit and comprehensive profit for the period	-	237	237
At 31 December 2010	2	237	239

The accompanying notes on pages 6 to 8 form an integral part of these non-consolidated financial statements.

CDC SCOTS GP LIMITED

Statement of cash flows

For the period 7 June 2010 to 31 December 2010

	US\$
Cash flows from operating activities	
Profit before tax	330
Profit before working capital changes	330
Increase in amounts payable to parent company	170
Net cash inflow from operating activities	500
Cash flows from investing activities	
Purchase of investments	(1)
Net cash outflow from investing activities	(1)
Cash flows from financing activities	
Issue of share capital	2
Net cash inflow from financing activities	2
Net increase in cash and cash equivalents	501
Cash and cash equivalents, beginning of the period	-
Cash and cash equivalents, end of year	501

The accompanying notes on pages 6 to 8 form an integral part of these non-consolidated financial statements.

CDC SCOTS GP LIMITED

Notes to the financial statements
For the period 7 June 2010 to 31 December 2010

1. Incorporation, ownership and principal activity

CDC Scots GP Limited (the "Company") was incorporated under the laws of Scotland on 7th June 2010 (the Company number is 379812). It is a wholly owned subsidiary of CDC Group plc, a public limited company incorporated in England and Wales whose registered office is Level 2, Cardinal Place, 80 Victoria Street, London SW1E 5JL, United Kingdom.

The Company's registered office is located at the 50 Lothian Road, Festival Square, Edinburgh EH3 9WJ, Scotland.

The principal activity of the Company is that of an investment company.

2. Significant accounting policies

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), which comprise standards and interpretations approved by the International Accounting Standards Board, and International Accounting Standards ("IAS") and Standing Interpretations Committee interpretations that remain in effect.

The financial statements are prepared on a historical cost basis except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

a) Basis of preparation

The financial statements have been prepared on a going concern basis.

b) Currency

The financial statements are expressed in US dollars.

Monetary assets and liabilities denominated in non-US dollar currency are translated into US dollars at exchange rates prevailing at the year end. Non-monetary assets and liabilities and transactions occurring in non-US dollar currency are translated at the rates of exchange prevailing on the date of each transaction. Exchange gains and losses are dealt with in the non-consolidated statement of comprehensive income.

CDC SCOTS GP LIMITED

Notes to the financial statements
For the period 7 June 2010 to 31 December 2010

2. Significant accounting policies (continued)

c) Equity investments

Investments are valued in accordance with IAS 39 (Financial Instruments: Recognition and Measurement). Investments consist of unquoted equity. All equity investments are classified as held-for-trading and held at fair value with any resultant gain or loss in value recognised in the non-consolidated statement of comprehensive income.

Investments are valued in accordance with CDC Group plc's equity valuation guidelines, which are developed in accordance with the International Private Equity and Venture Capital Association Valuation Guidelines.

Investments are valued at fair value, which is the amount for which an asset could be exchanged between knowledgeable, willing parties in an arm's length transaction, as follows:

- investments where fair value derives mainly from the underlying assets, such as funds managed by fund managers, are valued at net asset value using appropriate valuation measures for the underlying assets and liabilities;
- realisations in process are valued at the expected realisation proceeds, although discounts are applied to reflect the level of certainty of the transaction completion;
- if there has been a recent investment in the company, the price of the recent investment, less any impairment charge, is used to determine fair value;
- early stage companies without positive cash flow or profit are valued using an appropriate industry benchmark if that gives a reliable estimate of fair value;
- companies with maintainable profits or cash flows are valued on an earnings basis using an appropriate earnings multiple from companies in similar sectors and markets;
- companies in industries with specific valuation metrics are valued using those specific valuation metrics where they provide the most reliable estimate of fair value;
- companies with no maintainable profits or cash flows at present, but whose cash flows can be forecast with confidence, are valued using future cash flows discounted at the appropriate risk-adjusted discount rate; and
- in exceptional cases, where fair value cannot be reliably measured, the investment is valued at the previous carrying value unless there is evidence of value impairment, in which case value is reduced to reflect the extent of estimated impairment.

d) Revenue recognition

Interest is recognised as earned on an accruals basis, but is excluded if it becomes more than ninety days overdue. Investment income is accounted for on an accruals basis unless collectability is in doubt.

e) Cash and cash equivalents

Cash comprises cash at bank. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

f) Related parties

Parties are considered to be related to the Company if they have the ability, directly or indirectly, to control the Company or exercise significant influence over the Company in making financial and operating decisions, or vice versa, or where the Company is subject to common control or common significant influence.

g) New standards and interpretations

The following standards and interpretations were effective for accounting periods commencing on or after 1 January 2010: IFRS 5 (revised), Non Current Assets Held for Sale and Discontinued Operations; IAS 7 (revised), Statement of Cash Flows; and IAS 17(revised), Leases.

The Directors judge that the adoption of these standards has not had a material impact on the Company's financial statements in the period of initial application.

CDC SCOTS GP LIMITED

Notes to the financial statements
For the period 7 June 2010 to 31 December 2010

2. Significant accounting policies (continued)

h) Taxation

The tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the period.

Current and deferred taxes are recognised as a tax credit or expense in the year in which they arise except for deferred taxes recognised or disposed of upon the acquisition or disposal of a subsidiary.

Deferred tax is provided in full using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are expected to apply in the periods in which temporary differences reverse, based on tax rates and laws enacted or substantially enacted at the statement of financial position date.

Deferred tax assets are recognised only to the extent that the Directors consider that it is probable that there will be suitable taxable profits from which the future reversal of the underlying temporary differences can be deducted.

3. Related party transactions

The following are related party transactions and balances to the period ending 31 December 2010. All transactions are carried out on an arm's length basis.

Name of company / partnership	Nature of relationship	Nature of transactions / balances	US\$
Transactions during the year			
CDC Scots LP	Investment in limited partnership	Half of annual priority share	500
CDC Group plc	Parent company	Movement in current account	170
Balances outstanding at 31 December			
CDC Group plc	Parent company	Current account	170

Appendix: CDC SCOTS LP

Report of the General Partner
For the period 8 June 2010 to 31 December 2010

The General Partner is pleased to present their report together with the financial statements of CDC Scots LP (the "Partnership") for the period ended 31 December 2010.

Partners

CDC Scots GP Ltd
CDC Group plc

General Partner since 8 June 2010
Limited Partner since 8 June 2010

Principal activity

The principal activity of the Partnership is that of investment holding.

Business and performance review

The Partnership recorded a net profit of \$329,502 for the period from incorporation (8 June 2010) to the period end date of 31 December 2010. The net profit is principally attributable to an increase in the fair value of its investments which were valued at \$19,836,045 at 31 December 2010.

Principal risks

The Partnership invests in private equity funds in developing countries. The Partnership values its portfolio according to CDC Group plc's (CDC) valuation methodology. CDC valuation guidelines have been developed in accordance with the International Private Equity and Venture Capital Valuation Guidelines. Investments are valued at fair value, which is the value at which an orderly transaction would take place between market participants at the reporting date.

The detailed valuation methodology sets out best practice with respect to valuing investments.

Valuation risks are mitigated by comprehensive reviews of underlying investments in the private equity funds carried out by the managers of the private equity funds at least twice each year.

On behalf of the general partner



Godfrey Davies
Director of CDC Scots GP Ltd, general partner to CDC Scots LP

**PARTNERSHIP
ACCOUNTS**

Appendix: CDC SCOTS LP

Statement of comprehensive income
For the period 8 June 2010 to 31 December 2010

	US\$
Revenues	
Investment fair value gains	330,795
	<u>330,795</u>
Expenses	
General and administrative expenses	(793)
Half of annual priority share	(500)
	<u>(1,293)</u>
Net profit and comprehensive profit for the period	<u>329,502</u>

The accompanying notes on pages 14 to 17 form an integral part of these financial statements.


Appendix: CDC SCOTS LP

Statement of financial position
At 31 December 2010

	Notes	US\$
ASSETS		
Non-current assets		
Equity investments	3	19,836,045
Total non current assets		19,836,045
Current assets		
Cash and cash equivalents		53,059
Loan facility to investment fund	4	2,123,588
Total current assets		2,176,647
Total assets		22,012,692
LIABILITIES AND PARTNERS' EQUITY		
Current liabilities		
Amounts due to parent company	5	21,682,189
Total current liabilities		21,682,189
Partners' equity		
Issued partners' capital		1,001
Accumulated reserves		329,502
Total partners' equity		330,503
Total partners' equity and liabilities		22,012,692

The accompanying notes on pages 14 to 17 form an integral part of these financial statements.

Approved on behalf of the general partner on 10th October 2011



Godfrey Davies, Director of CDC Scots GP Ltd, general partner to CDC Scots LP (Partnership number 7946)

Appendix: CDC SCOTS LP

Statement of changes in equity

For the period 8 June 2010 to 31 December 2010

	Partners' capital US\$	Accumulated reserve US\$	Total US\$
At June 8, 2010	-	-	-
Issue of partners' capital	1,001	-	1,001
Net profit and comprehensive profit for the period	-	329,502	329,502
At 31 December 2010	1,001	329,502	330,503

The accompanying notes on pages 14 to 17 form an integral part of these financial statements.

Appendix: CDC SCOTS LP

Statement of cash flows

For the period 8 June 2010 to 31 December 2010

	US\$
Cash flows from operating activities	
Profit before tax	329,502
Profit before working capital changes	329,502
Investment fair value gains	(330,795)
Net cash inflow from operating activities	(1,293)
Cash flows from investing activities	
Purchase of investments	(3,130,715)
Proceeds from sale of investments	242,402
Net cash outflow from investing activities	(2,888,313)
Cash flows from financing activities	
Issue of partners' capital	1,001
Loan advances due to parent company	2,941,664
Net cash inflow from financing activities	2,942,665
Net increase in cash and cash equivalents	53,059
Cash and cash equivalents, beginning of the period	-
Cash and cash equivalents, end of year	53,059

The accompanying notes on pages 14 to 17 form an integral part of these financial statements.

Appendix: CDC SCOTS LP

Notes to the financial statements
For the period 8 June 2010 to 31 December 2010

1. Registration, ownership and principal activity

CDC Scots LP (the "Partnership") was registered as a limited partnership under the laws of Scotland on 8th June 2010 (the Partnership number is 7946). The Partnership was constituted by CDC Scots GP Limited (incorporated in Scotland whose registered office is located at the 50 Lothian Road, Festival Square, Edinburgh EH3 9WJ, Scotland) and CDC Group plc (a public limited company incorporated in England and Wales whose registered office is Level 2, Cardinal Place, 80 Victoria Street, London SW1E 5JL, England) under the terms of a limited partnership agreement dated 8 June 2010.

The Company's registered office is located at the 50 Lothian Road, Festival Square, Edinburgh EH3 9WJ, Scotland.

The principal activity of the Partnership is that of investment holding.

2. Significant accounting policies

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), which comprise standards and interpretations approved by the International Accounting Standards Board, and International Accounting Standards ("IAS") and Standing Interpretations Committee interpretations that remain in effect.

The financial statements are prepared on a historical cost basis except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

a) Basis of preparation

The financial statements have been prepared on a going concern basis.

The Partnership has elected not to present consolidated financial statements since its accounts are consolidated into those of CDC Group plc, the ultimate parent company. These accounts are available from Level 2, Cardinal Place, 80 Victoria Street, London SW1E 5JL, United Kingdom.

b) Currency

The financial statements are expressed in US dollars.

Monetary assets and liabilities denominated in non-US dollar currency are translated into US dollars at exchange rates prevailing at the year end. Non-monetary assets and liabilities and transactions occurring in non-US dollar currency are translated at the rates of exchange prevailing on the date of each transaction. Exchange gains and losses are dealt with in the non-consolidated statement of comprehensive income.

Appendix: CDC SCOTS LP

Notes to the financial statements
For the period 8 June 2010 to 31 December 2010

2. Significant accounting policies (continued)

c) Equity investments

Investments are valued in accordance with IAS 39 (Financial Instruments: Recognition and Measurement). Investments consist of unquoted equity. All equity investments are classified as held-for-trading and held at fair value with any resultant gain or loss in value recognised in the non-consolidated statement of comprehensive income.

Investments are valued in accordance with CDC Group plc's equity valuation guidelines, which are developed in accordance with the International Private Equity and Venture Capital Association Valuation Guidelines.

Investments are valued at fair value, which is the amount for which an asset could be exchanged between knowledgeable, willing parties in an arm's length transaction, as follows:

- investments where fair value derives mainly from the underlying assets, such as funds managed by fund managers, are valued at net asset value using appropriate valuation measures for the underlying assets and liabilities;
- realisations in process are valued at the expected realisation proceeds, although discounts are applied to reflect the level of certainty of the transaction completion;
- if there has been a recent investment in the company, the price of the recent investment, less any impairment charge, is used to determine fair value;
- early stage companies without positive cash flow or profit are valued using an appropriate industry benchmark if that gives a reliable estimate of fair value;
- companies with maintainable profits or cash flows are valued on an earnings basis using an appropriate earnings multiple from companies in similar sectors and markets;
- companies in industries with specific valuation metrics are valued using those specific valuation metrics where they provide the most reliable estimate of fair value;
- companies with no maintainable profits or cash flows at present, but whose cash flows can be forecast with confidence, are valued using future cash flows discounted at the appropriate risk-adjusted discount rate; and
- in exceptional cases, where fair value cannot be reliably measured, the investment is valued at the previous carrying value unless there is evidence of value impairment, in which case value is reduced to reflect the extent of estimated impairment.

d) Revenue recognition

Interest is recognised as earned on an accruals basis, but is excluded if it becomes more than ninety days overdue. Investment income is accounted for on an accruals basis unless collectability is in doubt.

e) Cash and cash equivalents

Cash comprises cash at bank. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

f) Related parties

Parties are considered to be related to the Partnership if they have the ability, directly or indirectly, to control the Partnership or exercise significant influence over the Partnership in making financial and operating decisions, or vice versa, or where the Partnership is subject to common control or common significant influence.

g) New standards and interpretations

The following standards and interpretations were effective for accounting periods commencing on or after 1 January 2010: IFRS 5 (revised), Non Current Assets Held for Sale and Discontinued Operations; IAS 7 (revised), Statement of Cash Flows; and IAS 17(revised), Leases.

The Directors of CDC Scots GP Ltd, general partner to CDC Scots LP judge that the adoption of these standards has not had a material impact on the Company's financial statements in the period of initial application.

Appendix: CDC SCOTS LP

Notes to the financial statements
For the period 8 June 2010 to 31 December 2010

3. Equity investments

Equity investments are all unquoted.

	US\$
At 8 June 2010, at fair value	-
Transferred from CDC Group plc	16,616,937
Additions	3,130,715
Disposals	(242,402)
Increase in fair value for the period	330,795
At 31 December 2010, at fair value	19,836,045

The above investments were associates of the Company as at 31 December 2010:

Name of Company	% Holding	Country of incorporation
Aureos Latin America Fund	28.3	Canada
Seedfund 2	24.2	Mauritius

Unquoted equity investments are included within Level 3 of the fair value hierarchy. The Company holds no Level 1 or Level 2 investments.

The different levels have been defined as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the assets, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset that are not based on observable market data (unobservable inputs).

4. Loan facility to investment fund

In June 2010, CDC Group plc made available to Aureos Latin America Fund a term loan facility of up to \$2,123,588 and is payable upon demand by CDC Group plc at any time after 30 July 2010. In June 2010, this term loan facility was assigned from CDC Group plc to CDC Scots LP.

5. Amounts due to parent company

	US\$
Loan due to CDC Group plc	19,413,664
Creditor within one year due to CDC Group plc	2,268,525
At 31 December 2010, at fair value	21,682,189

Appendix: CDC SCOTS LP

Notes to the financial statements
For the period 8 June 2010 to 31 December 2010

6. Related party transactions

The following are related party transactions and balances to the period ending 31 December 2010. All transactions are carried out on an arm's length basis.

Name of company / partnership	Nature of relationship	Nature of transactions / balances	US\$
Transactions during the year			
CDC Scots GP	General partner	Half of annual priority share	500
CDC Group plc	Parent company	Transfer of equity investments	16,616,937
CDC Group plc	Parent company	Movement in current account	2,268,525
CDC Group plc	Parent company	Movement in loan due	19,413,664
Balances outstanding at 31 December			
CDC Group plc	Parent company	Current account	2,268,525
CDC Group plc	Parent company	Loan due	19,413,664